- Home
- MACI vs YMAB Comparison
MACI vs YMAB Comparison
Compare MACI & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MACI
- YMAB
- Stock Information
- Founded
- MACI 2024
- YMAB 2015
- Country
- MACI United States
- YMAB United States
- Employees
- MACI N/A
- YMAB N/A
- Industry
- MACI
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MACI
- YMAB Health Care
- Exchange
- MACI NYSE
- YMAB Nasdaq
- Market Cap
- MACI 221.6M
- YMAB 192.4M
- IPO Year
- MACI 2024
- YMAB 2018
- Fundamental
- Price
- MACI $10.37
- YMAB $4.60
- Analyst Decision
- MACI
- YMAB Buy
- Analyst Count
- MACI 0
- YMAB 11
- Target Price
- MACI N/A
- YMAB $17.55
- AVG Volume (30 Days)
- MACI 9.4K
- YMAB 226.0K
- Earning Date
- MACI 01-01-0001
- YMAB 05-13-2025
- Dividend Yield
- MACI N/A
- YMAB N/A
- EPS Growth
- MACI N/A
- YMAB N/A
- EPS
- MACI 0.33
- YMAB N/A
- Revenue
- MACI N/A
- YMAB $88,658,000.00
- Revenue This Year
- MACI N/A
- YMAB N/A
- Revenue Next Year
- MACI N/A
- YMAB $16.03
- P/E Ratio
- MACI $31.51
- YMAB N/A
- Revenue Growth
- MACI N/A
- YMAB 4.92
- 52 Week Low
- MACI $9.95
- YMAB $3.55
- 52 Week High
- MACI $10.40
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- MACI N/A
- YMAB 56.43
- Support Level
- MACI N/A
- YMAB $3.99
- Resistance Level
- MACI N/A
- YMAB $5.00
- Average True Range (ATR)
- MACI 0.00
- YMAB 0.35
- MACD
- MACI 0.00
- YMAB 0.10
- Stochastic Oscillator
- MACI 0.00
- YMAB 70.47
About MACI MELAR ACQUISITION CORP. I
Melar Acquisition Corp I is a blank check company.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.